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Bayesian Dose Finding for Combined Drugs
with Discrete and Continuous Doses
Lin Huo∗, Ying Yuan† and Guosheng Yin‡
Abstract. The trend of treating patients with combined drugs has grown in
cancer clinical trials. Often, evaluating the synergism of multiple drugs is the pri-
mary motivation for such drug-combination studies. To enhance patient response,
a new agent is often investigated together with an existing standard of care (SOC)
agent. Often, a certain amount of dosage of the SOC is administered in order
to maintain at least some therapeutic effects in patients. For clinical trials in-
volving a continuous-dose SOC and a discrete-dose agent, we propose a two-stage
Bayesian adaptive dose-finding design. The first stage takes a continual reassess-
ment method to locate the appropriate dose for the discrete-dose agent while fixing
the continuous-dose SOC at the minimal therapeutic dose. In the second stage,
we make a fine dose adjustment by calibrating the continuous dose to achieve the
target toxicity rate as closely as possible. Dose escalation or de-escalation is based
on the posterior estimates of the joint toxicity probabilities of combined doses. As
the toxicity data accumulate during the trial, we adaptively assign each cohort of
patients to the most appropriate dose combination. We conduct extensive simu-
lation studies to examine the operating characteristics of the proposed two-stage
design and demonstrate the design’s good performance with practical scenarios.
Keywords: Bayesian adaptive design, Combined drugs, Continual reassessment
method, Maximum tolerated dose, Phase I trial, Toxicity probability, Two-stage
design
1 Introduction
The typical goal of a phase I clinical trial in oncology is to identify the maximum
tolerated dose (MTD), which is defined as the dose with a toxicity probability closest to
the physician-specified target toxicity rate. Since little is known about the MTD at such
an early stage of a drug study, most phase I clinical trials start with a low dose level
that is presumed safe. From that point, the toxicity probability at each dose level can
be continuously estimated based on the accumulating data, and patients are adaptively
assigned to the appropriate dose levels.
Numerous methods have been proposed for designing phase I clinical trials, most
of which have an underlying assumption that the dose-toxicity curve is monotonically
increasing. For example, the algorithm-based 3+3 design is a conventional method
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that often locates the MTD as the dose with a toxicity probability less than 33%;
see Storer (1989). The 3+3 design is commonly used in practice due to its simplicity;
however, the estimates of the toxicity probabilities may not be stable. As an alternative,
the continual reassessment method (CRM) developed by O’Quigley, Pepe and Fisher
(1995) assumes a parametric link function between the true toxicity probabilities and
the physician-specified toxicity probabilities. This model-based dose-finding method
efficiently estimates the single unknown parameter in the link function, updates the
posterior estimates of the toxicity probabilities, and eventually locates the MTD from
the doses under consideration. Criticism of the original CRM for a tendency to allocate
many patients to overly toxic doses has led to the development of several modifications
to improve its performance. Goodman, Zahurak and Piantadosi (1995) developed a
modified version of the CRM that allocates patients with a cohort size larger than one
to each dose level and constrains the dose escalation by one level at a time. Møller (1995)
combined the CRM with a preliminary up-and-down design to reach the neighborhood of
the target dose while also limiting the dose escalation to a single dose level. Piantadosi,
Fisher and Grossman (1998) implemented the CRM with a simple dose-toxicity model
to guide data interpolation. Heyd and Carlin (1999) formulated a stopping rule to
terminate the trial if the width of the 95% posterior probability interval for the MTD is
within certain limits. Ishizuka and Ohashi (2001) extended the CRM by monitoring a
posterior density function of the occurrence of the dose-limiting toxicity (DLT) at each
dose level. Leung and Wang (2002) used the theory of decision processes to find optimal
allocations that maximize the expected number of patients assigned to the MTD. Yuan,
Chappell and Bailey (2007) developed a quasi-likelihood approach to accommodating
multiple toxicity grades. To improve the robustness of the CRM, Yin and Yuan (2009a)
proposed to use multiple prespecified toxicity probabilities in the CRM model and take a
Bayesian model averaging (BMA) approach to estimating the true toxicity probabilities.
Comprehensive reviews and discussions of statistical methods for phase I trial designs
can be found in Chevret (2006) and Yin (2012).
All of the aforementioned methods are developed for single-agent dose-finding trials,
and thus cannot address the issues in drug-combination studies. Combining different
agents may induce synergistic treatment effects, target different disease pathways, and
achieve high dose intensities with non-overlapping toxicities. However, complex drug-
drug interactions may also lead to unknown toxicity patterns and thus make it difficult
to fully rank the toxicities of all dose combinations. This is particularly true for the dose
pairs along the off-diagonal directions in the two-dimensional dose-finding matrix. In the
area of drug-combination studies, Korn and Simon (1993) introduced a tolerable dose
diagram to provide guidance in targeting specific MTD combinations. Kramar, Lebecq
and Candalh (1999) proposed searching over a selected subset of drug combinations
that still maintains the monotonic toxicity order. For a trial combining paclitaxel and
carboplatin to treat ovarian cancer, Kuzuya et al. (2001) proposed fixing one agent at
each dose level and varying the dose level of the other. Thall et al. (2003) proposed a six-
parameter model for the joint toxicity probability of the combination of gemcitabine and
cyclophosphamide. The two drugs are modeled as two continuous-dose agents because
their dosages can be given at any arbitrary amount through intravenous administration.
Wang and Ivanova (2005) studied a log-linear model by using the standardized doses of
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two drugs as the covariates. Yuan and Yin (2008) developed a sequential design scheme
for drug-combination trials, which uses the partial order of the two-dimensional dose-
finding space. Through incorporating the prior information on the toxicity probabilities
when each drug is administered alone, Yin and Yuan (2009b) proposed a copula-type
regression to model the joint toxicity probabilities of combined drugs. Braun and Wang
(2010) developed a Bayesian hierarchical model for the probabilities of the DLTs for
combined doses of two therapeutic agents. Wages, Conaway and O’Quigley (2011)
investigated the CRM with partial ordering in two-dimensional dose-finding trials. Most
of the drug-combination dose-finding methods focus on the cases for which the dosages of
both drugs in the combination are discrete and are often prepared in tablets, except for
the work of Thall et al. (2003) which investigates the combination of two intravenously
administered drugs with continuous doses.
Our research is motivated by a clinical trial in metastatic renal cell carcinoma (RCC),
which investigated the combination of the standard of care, temsirolimus, with a new
agent for RCC patients. The new agent was administered orally at five dose levels and
temsirolimus was administered by intravenous infusion. By targeting different disease
pathways, the combined drugs are expected to induce a synergistic treatment effect.
The primary objective of this trial is to find the MTD combination of the new therapy
and temsirolimus with the target toxicity probability of 0.3. There may be multiple
MTD combinations because of the dose-toxicity contour in the two-dimensional dose
combination space. In this design, we focus on finding one single MTD combination,
for which the toxicity probability of the identified discrete dose in combination with the
minimal therapeutic continuous dose must be below but closest to the toxicity target.
This allows for a further fine adjustment through the continuous dose in order to reach
the target toxicity probability as closely as possible. Toward this goal, we propose a
robust two-stage CRM design for clinical trials combining a discrete-dose agent and a
continuous-dose agent. The first stage adopts the conventional CRM to locate the most
appropriate dose for the discrete-dose agent, while fixing the continuous-dose agent at
the minimum baseline dose specified by physicians. The second stage searches for the
best dose combination of the continuous and discrete agents by continuously updating
the posterior estimates of the toxicity probabilities for the combined doses. If the
discrete dose is overestimated or underestimated in stage I, it can still be adjusted in
stage II. Based on the accumulating data, we adaptively assign each cohort of patients
to the most appropriate dose combination throughout the trial.
The rest of the paper is organized as follows. In Section 2, we propose the two-
stage CRM design to jointly locate the maximum tolerated dose combination, and we
also present the likelihood function and the posterior distribution for the unknown
parameters. In Section 3, we describe the dose-finding algorithm in detail. We conduct
extensive simulation studies to examine the operating characteristics of the proposed
design in Section 4. Finally, we conclude with a brief discussion in Section 5.
1038 Bayesian Dose Finding
2 Two-stage Dose Finding
2.1 Continual Reassessment Method
Suppose that there are J predetermined doses for the discrete-dose agent under study,
and let (p1, . . . , pJ) represent a set of prespecified toxicity probabilities (known as the
skeleton in the CRM) at those doses. We assume that toxicity monotonically increases
with respect to dose levels, i.e., p1 < · · · < pJ , and denote φ as the target toxicity rate.
A commonly used one-parameter CRM model is given as
Pr(toxicity at dose level d) = pid(α) = p
exp(α)
d (1)
for d = 1, . . . , J . In this model, a power function with an unknown parameter α links
the true toxicity probabilities with the prespecified toxicity probabilities.
Suppose that n patients have entered the trial, and let di and yi denote the received
dose level and the toxicity outcome for the ith subject, respectively. The toxicity out-
come is taken as a Bernoulli variable, i.e., yi = 1 with probability pidi(α), and 0 with
probability 1−pidi(α). The likelihood function based on the observed toxicity outcomes
y = {yi, i = 1, . . . , n} is then given by
L(α|y) ∝
n∏
i=1
{pexp(α)di }yi{1− p
exp(α)
di
}1−yi .
In the Bayesian paradigm, let f(α) denote the prior distribution for the parameter α,
and we can estimate the toxicity probabilities by their posterior means,
pˆid =
∫
p
exp(α)
d
L(α|y)f(α)∫
L(α|y)f(α)dαdα, d = 1, . . . , J.
Based on these toxicity probability estimates, we assign the next cohort of patients to
dose level d(I), which has the toxicity probability closest to the target rate. Let dcurr
denote the current dose level, then
d(I) = argmind≤dcurr+1|pˆid − φ|, (2)
which restricts dose escalation by one dose level only. The trial continues till exhausting
the total sample size, and then the dose with a posterior toxicity probability closest to
φ is selected as the MTD.
2.2 Two-stage Continual Reassessment Method
For a set of prespecified discrete doses and an unspecified continuous dose of two drugs
in combination, we propose a two-stage CRM design to locate the MTD combination.
For convenience, we denote the discrete-dose agent as A with prespecified doses, A1 <
· · · < AJ , and the continuous-dose agent as B, whose dose is unspecified but the initial
minimal dose is given. In stage I, fixing B at the prespecified minimal dose z0, we
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Figure 1: Illustration of the two-stage CRM. Each cohort is represented by a circle
and numbered by the cohort’s order in the trial at the corresponding dose combination.
The star symbol represents the target dose combination with a toxicity probability of
0.3. Stage I takes five cohorts to select the target discrete dose 3; and stage II uses the
remaining four cohorts to estimate the continuous dose in combination with the discrete
dose 3.
adopt the traditional CRM model to find the appropriate dose level of A to be used in
combination with B such that the joint toxicity probability is closest to but not higher
than the prespecified target toxicity rate φ. In stage II, we employ a two-parameter
CRM model to calibrate the dose of B to achieve the target toxicity rate φ as closely
as possible. The intuition behind our approach is that we first take a crude search over
discrete doses of A to reach the neighborhood but lower than the target, and then make
a fine adjustment by calibrating the continuous dose of B. This two-stage dose-finding
procedure is illustrated in Figure 1: The first five cohorts of patients are used in stage
I to locate the target discrete dose and the remaining four cohorts are treated in stage
II to determine the continuous dose. Even in stage II, the discrete dose can still be
adjusted if it is under- or overestimated in stage I.
Let z (z ≥ z0) denote the continuous dose in the drug combination. We propose a
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two-parameter model in the two-stage CRM design,
Pr(toxicity at dose level d of A and dose z of B) = pid(z) = p
exp(α−β(z−z0))
d (3)
for d = 1, . . . , J , where α and β are unknown parameters. We require β > 0, so that the
monotonic toxicity assumption still holds for the continuous-dose agent when fixing the
discrete dose. Via a simple transformation, model (3) can be rewritten as a generalized
linear model of the form
log[− log{pid(z)}] = log{− log(pd)}+ α− β(z − z0).
Therefore, natural choices for the prior distributions of α and β are α ∼ N(0, σ2) and
β ∼ Ga(a, b), where N(0, σ2) denotes a normal distribution with mean 0 and variance
σ2 and Ga(a, b) denotes a gamma distribution with shape and rate parameters a and
b. As the effects of α and β on the toxicity probability pid(z) are on the complementary
log–log scale, setting the values of these hyperparameters such as σ2 = 2 and a = b = 0.1
would lead to adequately vague priors, such that the data will dominate the posterior
distribution.
Our design consists of two sequential stages with a prespecified sample size N1 for
stage I and N2 for stage II. In stage I, we fix the continuous-dose agent at the baseline
dose z0 and only consider dose escalation and de-escalation for the discrete dose. By
taking z = z0, the two-parameter CRM model (3) reduces to the usual CRM model (1),
and thus the conventional CRM as described in Section 2.1 can be directly used for dose
finding in stage I. After N1 patients are used up, we identify the discrete dose together
with z0 that should have an estimated toxicity probability closest to but not greater
than the target φ. It is worth emphasizing that the selected discrete dose together with
the minimum continuous dose z0 should have a toxicity probability smaller than φ, so
that we will still have some room to search for the desirable continuous dose in stage II.
Assume that, at a certain time point of stage II, an additional n2 patients have
been enrolled into the trial, and let zi denote the continuous dose assigned to the ith
patient, i = 1, . . . , N1 + n2. Certainly, zi = z0 for all the first N1 patients. Under the
two-parameter CRM model, the likelihood function is given by
L(α, β|y) ∝
N1+n2∏
i=1
{pexp(α−β(zi−z0))di }yi{1− p
exp(α−β(zi−z0))
di
}1−yi .
The unknown parameters α and β can be estimated by their posterior means:
αˆ =
∫ ∫
α
L(α, β|y)f(α)f(β)∫ ∫
L(α, β|y)f(α)f(β)dαdβ dαdβ,
βˆ =
∫ ∫
β
L(α, β|y)f(α)f(β)∫ ∫
L(α, β|y)f(α)f(β)dαdβ dαdβ,
where f(α) and f(β) are the prior distributions for α and β, respectively. Based on
these posterior estimates, we choose the discrete dose d(II) as the highest dose with a
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toxicity probability less than φ,
d(II) = max{d : pexp(αˆ)d ≤ φ and d ≤ dcurr + 1}, (4)
in which we impose the condition d ≤ dcurr+1 to enhance patient safety by restricting to
one-level dose escalation at most. We then determine the continuous dose z by solving
equation (3), that is,
φ = pexp(αˆ−βˆ(z−z0))
d(II)
,
which yields
z = z0 +
αˆ− log{log(φ)/log(pd(II))}
βˆ
. (5)
Thus, the identified dose combination (d(II), z) has an estimated toxicity probability φ
and will be used to treat the next cohort of patients. One of the appealing features of
the two-stage procedure is that we still update the discrete dose even in the second stage
by pooling all the information together, in order to achieve the goal of jointly searching
for the discrete and continuous doses.
2.3 Robust Two-stage CRM with Model Selection
Like the standard CRM, the two-stage CRM design also requires prespecification of a
set of arbitrary toxicity probabilities (skeleton). In an early stage trial, our knowledge
on the toxicity profile of a new drug, and especially a combination of new drugs, is very
limited. Hence, the prespecified skeleton could be quite subjective. If the skeleton is
misspecified, the performance of the CRM can be substantially compromised. To ad-
dress this issue, Yin and Yuan (2009a) proposed to use multiple skeletons in the CRM
and take a Bayesian model averaging (BMA) approach to obtaining robust estimates
of the toxicity probabilities. Following this route, we propose prespecifying multiple
skeletons and then use the model selection procedure to overcome the possible mis-
specification of the skeleton. Compared with the BMA approach, model selection is
computationally straightforward and easier to implement. In particular, we can elicit
two or more skeletons for the discrete doses, and each skeleton represents a prior guess
of the toxicity profile of the discrete-dose agent. We view the CRM model under each
set of the prespecified toxicity probabilities as a separate model, and use the Bayesian
information criterion (BIC) to select the best-fitting model to make inference on the
unknown parameters and determine the dose assignment.
More specifically, let {(p11, . . . , p1J ), . . . , (pK1, . . . , pKJ)} denote K sets of prior
guesses of the toxicity probabilities (i.e., skeletons) for the discrete-dose agent. Each of
the skeletons leads to a dose-toxicity model of the form
pikd(z) = p
exp(α−β(z−z0))
kd , d = 1, . . . , J,
resulting in a total of K candidate models {M1, . . . ,MK}, where Mk denotes the model
based on the kth skeleton (pk1, . . . , pkJ). Note that the K candidate models share the
same structure and the only difference is that they use different values for the skeleton.
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During the trial, after each new cohort of patients enters the trial, in light of the
most recent observations, we fit each of the K candidate models independently and
calculate the corresponding BIC,
BICk = −2logL(α, β|y,Mk) + r log(n),
where r is the number of model parameters and n is the total number of patients enrolled
in the trial thus far. We select the best-fitting model that yields the lowest value of
the BIC, and under the selected model, we can estimate the toxicity probability of each
dose and guide the next dose assignment. Consequently, we are able to locate the target
dose combination in a more reliable way and to treat the patients at more appropriate
doses.
3 Dose-finding Algorithm
Let φ be the physician-determined toxicity target, and let z0 be the prespecified minimal
baseline continuous dose. Our two-stage dose-finding algorithm is described as follows.
Stage I:
1. The first cohort of patients receives the lowest dose combination (A1, z0).
2. Based on the accumulated data, we first select the best-fitting model and then
obtain the estimates of the dose toxicity probabilities under the selected model.
The next cohort of patients will be treated at the combination of (d(I), z0), where
d(I) is given by (2).
3. Once the maximum sample size N1 is reached, we complete stage I and select the
dose that has the toxicity probability closest to but less than φ as the starting
dose of the discrete-dose agent for stage II.
Stage II:
1. Based on the data collected in both stages I and II, we conduct model selection
and obtain the posterior estimates of the parameters α and β under the best-
fitting two-parameter CRM model. We treat the next cohort of patients at the
dose combination (d(II), z), where d(II) is given by (4) and the continuous dose z
is given by (5).
2. Once the total sample size of the trial, N1+N2, is reached, we select the updated
dose combination (d(II), z) as the MTD based on all the observations.
For safety, we impose a stopping rule in the dose-finding algorithm: If the toxicity
probability at the lowest dose combination is still overly toxic as noted by
Pr(toxicity rate at A1 and z0 is greater than φ | data) > 0.9,
we terminate the trial.
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4 Numerical Studies
4.1 Simulation Studies
We investigated the performance of the proposed robust two-stage CRM design through
simulation studies under eight different scenarios. We took a cohort size of 2, and
allocated 8 cohorts in stage I and 10 cohorts in stage II, that is, N1 = 16 and N2 = 20.
We assumed that toxicity monotonically increased with doses and the target toxicity
probability was φ = 0.3. For the continuous-dose agent, we standardized the baseline
dose z0 = 1; and for the discrete-dose agent, we considered five dose levels. In Table
1, we list the true toxicity probabilities for the discrete doses and the target continuous
dose in the first row under each scenario. The target discrete dose is highlighted with
an underline, which is the one having a toxicity probability closest to but not higher
than the target toxicity probability.
To implement the proposed robust two-stage CRM, we elicited three sets of prior
guesses of the toxicity probabilities:
(p1, p2, p3, p4, p5) =
 (0.05, 0.14, 0.18, 0.22, 0.30), skeleton 1,(0.08, 0.12, 0.30, 0.40, 0.50), skeleton 2,(0.20, 0.30, 0.40, 0.50, 0.60), skeleton 3.
The three skeletons represent quite different toxicity profiles. The first skeleton is con-
centrated on the low toxicity levels with a toxicity probability of 0.3 at the highest
dose. The second skeleton has the target in the middle and represents the case in which
toxicity increases slowly at the low doses but quickly at the high doses. The toxicity
probabilities in the third skeleton are evenly distributed over the range of 0.2 to 0.6.
We compare the performance of the two-stage CRM using each skeleton alone and the
robust version of using model selection with all three skeletons. We refer to the indi-
vidual two-stage CRMs using each of these three skeletons as CRM2S 1, CRM2S 2, and
CRM2S 3, and let CRM2S-MS denote the proposed robust two-stage CRM with model
selection. We simulated 1,000 trials under each scenario.
Table 1 shows the simulation results, including the selection probabilities of discrete
doses, and the 25th, 50th and 75th percentiles of the identified continuous doses. We also
report the average number of patients treated at each discrete dose, the average number
of patients who experienced toxicity, the average number of patients treated in the entire
trial, and the percentage of inconclusive trials (i.e., the trials that were early stopped due
to excessive toxicity, denoted by the last column “None”). In scenario 1, the first dose is
the target discrete dose; the three individual two-stage CRMs using different skeletons
selected the target discrete dose with quite different percentages, indicating that the
two-stage CRM is sensitive to the specification of the skeleton. In particular, CRM2S
2 (corresponding to the design using skeleton 2) had the lowest selection percentage of
48.7% for the target discrete dose, and the smallest estimate of the continuous dose,
1.12, compared with the target continuous dose of 1.46. By contrast, the proposed
CRM2S-MS selected the target discrete dose with a percentage of 63.7% and estimated
the continuous dose as 1.39. Clearly in this scenario, the CRM2S-MS performed much
better than CRM2S 2 and CRM2S 3. The number of patients treated at each dose
1044 Bayesian Dose Finding
Table 1: Simulation study of the two-stage CRM with a toxicity target of φ = 30%.
We present the selection percentage for each discrete dose (the target dose in boldface),
the average number of patients treated at each dose, and the median of the estimated
continuous dose along with the 25th and 75th percentiles. The last three columns
correspond to the average number of observed toxicities, the average number of patients
in the trial, and the percentage of inconclusive trials.
Two-stage Agent A (Discrete) Agent B Ave. Ave.
None
Design 1 2 3 4 5 (Continuous) # tox # pts
Scenario 1 0.22 0.35 0.45 0.60 0.70 1.46
CRM2S 1 76.2 8.5 3.4 0.3 0 1.41(1.19,1.77) 13.3 32.5 11.6
# patients 21.5 6.5 2.8 1.4 0.3
CRM2S 2 48.7 37.4 2.0 0.2 0 1.12(1.06,1.20) 14.8 32.5 11.7
# patients 16.2 12.9 2.7 0.6 0.1
CRM2S 3 61.8 24.7 2.6 0.2 0 1.26(1.10,1.65) 13.9 32.8 10.7
# patients 19.0 9.6 3.3 0.7 0.2
CRM2S-MS 63.7 23.1 2.1 0.2 0 1.39(1.19,1.73) 14.2 32.7 10.9
# patients 19.0 9.8 3.1 0.7 0.1
Scenario 2 0.10 0.25 0.45 0.55 0.65 1.28
CRM2S 1 56.3 27.1 13.4 2.2 0.1 1.08(1.04,1.21) 11.3 35.7 0.9
# patients 14.6 11.0 6.4 2.9 0.8
CRM2S 2 11.1 82.8 4.1 0.2 0 1.29(1.12,1.61) 11.8 35.4 1.8
# patients 6.8 21.5 5.6 1.2 0.3
CRM2S 3 24.4 62.9 10.5 0.8 0 1.23(1.09,1.54) 11.1 35.5 1.4
# patients 9.7 17.1 6.7 1.5 0.5
CRM2S-MS 27.2 65.1 5.7 0.8 0 1.30(1.14,1.65) 11.8 35.6 1.2
# patients 9.2 17.9 6.5 1.6 0.4
Scenario 3 0.14 0.21 0.35 0.49 0.63 1.52
CRM2S 1 44.9 22.2 22.2 8.4 0.1 1.10(1.05,1.22) 11.2 35.3 2.2
# patients 12.6 9.4 7.4 4.7 1.2
CRM2S 2 9.9 73.7 12.2 1.1 0.1 1.46(1.23,1.87) 11.5 35.0 3.0
# patients 6.7 18.4 7.5 2.0 0.5
CRM2S 3 17.8 48.3 29.1 1.9 0 1.30(1.12,1.63) 10.9 35.1 2.8
# patients 8.5 14.0 9.5 2.5 0.7
CRM2S-MS 19.3 63.3 12.5 2.5 0 1.47(1.27,1.86) 11.5 35.2 2.4
# patients 8.1 16.3 7.6 2.6 0.6
Scenario 4 0.08 0.15 0.22 0.35 0.50 1.46
CRM2S 1 10.0 10.2 29.3 45.1 4.5 1.07(1.03,1.14) 10.2 35.7 0.9
# patients 5.5 6.5 8.0 11.2 4.5
CRM2S 2 1.0 42.5 33.8 19.9 2.0 1.26(1.13,1.53) 9.9 35.7 0.8
# patients 3.6 12.2 11.2 6.5 2.2
CRM2S 3 2.1 20.6 49.1 25.8 1.8 1.33(1.12,1.62) 9.7 35.8 0.6
# patients 4.1 8.3 12.7 8.1 2.6
CRM2S-MS 4.0 35.2 38.1 19.8 2.0 1.25(1.13,1.51) 10.1 35.7 0.9
# patients 4.2 10.0 10.7 7.8 3.0
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Table 1, continued.
Two-stage Agent A (Discrete) Agent B Ave. Ave.
None
Design 1 2 3 4 5 (Continuous) # tox # pts
Scenario 5 0.05 0.10 0.20 0.40 0.54 1.58
CRM2S 1 3.8 9.6 38.8 44.8 2.6 1.07(1.03,1.15) 10.4 35.9 0.4
# patients 3.6 6.1 9.8 12.1 4.3
CRM2S 2 0 34.1 44.6 19.6 1.3 1.38(1.16,1.74) 10.0 35.9 0.4
# patients 2.6 9.7 13.9 7.5 2.2
CRM2S 3 0.1 12.5 64.4 20.8 1.8 1.35(1.15,1.71) 9.9 35.9 0.4
# patients 2.8 6.7 15.6 8.1 2.7
CRM2S-MS 0.3 31.7 50.2 16.5 1.0 1.35(1.14,1.71) 10.2 35.9 0.3
# patients 2.7 9.0 13.4 8.2 2.6
Scenario 6 0.02 0.08 0.12 0.20 0.40 1.58
CRM2S 1 0.2 1.1 4.8 57.5 36.4 1.19(1.08,1.47) 9.8 36 0
# patients 2.4 3.1 3.9 12.9 13.7
CRM2S 2 0 7.1 16.1 55.3 21.5 1.34(1.14,1.66) 9.1 36 0
# patients 2.3 4.4 7.6 12.6 9.1
CRM2S 3 0 1.4 16.5 62.2 19.9 1.37(1.15,1.80) 9.3 36 0
# patients 2.3 3.3 6.8 14.3 9.3
CRM2S-MS 0.1 4.4 13.0 55.9 26.6 1.32(1.13,1.66) 9.4 36 0
# patients 2.3 3.6 6.5 12.9 10.7
Scenario 7 0.02 0.05 0.08 0.12 0.25 1.28
CRM2S 1 0 0 0.2 14.2 85.6 1.37(1.15,1.72) 9.0 36 0
# patients 2.2 2.4 2.4 5.5 23.5
CRM2S 2 0 1.3 3.5 27.1 68.1 1.37(1.17,1.70) 8.4 36 0
# patients 2.2 2.8 4.2 8.1 18.7
CRM2S 3 0 0 2.2 31.3 66.5 1.36(1.16,1.72) 8.6 36 0
# patients 2.2 2.4 3.5 8.8 19.1
CRM2S-MS 0 0.6 2.0 23.0 74.4 1.38(1.17,1.72) 8.7 36 0
# patients 2.2 2.5 3.4 7.2 20.7
Scenario 8 0.50 0.60 0.65 0.70 0.80
CRM2S 1 24.8 0 0 0 0 9.1 13.5 75.2
# patients 12.1 1.1 0.2 0.1 0
CRM2S 2 22.4 0.1 0 0 0 8.8 13.0 77.5
# patients 11.4 1.4 0.2 0 0
CRM2S 3 23.3 0 0 0 0 8.9 13.2 76.7
# patients 11.7 1.2 0.3 0 0
CRM2S-MS 24.3 0.2 0 0 0 9.1 13.5 75.5
# patients 11.9 1.3 0.3 0 0
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was similar across all of the four designs, except that CRM2S 2 treated almost twice the
number of patients at dose level 2 as that of CRM2S 1. Scenario 2 has the target discrete
dose at the second dose level and the target continuous dose of 1.28. Both the selection
percentage of the target discrete dose and the estimate of the target continuous dose
using the CRM2S-MS ranked the second best among all of the four designs. Particularly,
the proposed CRM2S-MS design recommended the target discrete dose approximately
65% of the time and estimated the continuous dose as 1.30, which is very close to the
target value of 1.28. The worst skeleton corresponded to CRM2S 1, which yielded a very
low selection percentage of the target discrete dose, only 27.1%, but incorrectly selected
the first dose with a percentage of 56.3%. The continuous dose estimate of CRM2S 1
is only 1.08, which is far below the target continuous dose. Therefore, if skeleton 1
had been used for the trial conduct, the first dose would have been very likely selected.
This is due to overestimation of the toxicity probability, as the first dose has a very
low toxicity probability of only 0.1. Thus, inappropriately selecting the dose would
cause researchers to overlook an otherwise promising drug. Scenario 3 also has the
target discrete dose at the second dose level and has the target continuous dose of 1.52.
Again, CRM2S 1 had the worst performance overall; CRM2S-MS performed much better
with a selection percentage of 63.3% at the target discrete dose level and an estimated
continuous dose of 1.47. The third dose is the target discrete dose in both scenarios
4 and 5. Unfortunately in scenario 4, CRM2S 1 selected the fourth discrete dose with
45.1%, and CRM2S 2 selected the second discrete dose with 42.5%. None of these two
skeletons would lead to appropriate selection of the MTD combination. Compared with
the performances of CRM2S 1 and CRM2S 2, the CRM2S-MS selected dose level 3 as the
target dose with the highest percentage. In scenario 5, the CRM2S-MS had the second
best performance overall with respect to the target discrete dose selection percentage
and continuous dose estimation. From scenarios 6 and 7, similar conclusions can be
drawn: The CRM2S-MS design is indeed more robust than other versions of two-stage
CRMs. Scenario 8 provides an example of even the first dose being overly toxic; all the
designs terminated the trial early due to the implementation of the safety rule.
To further evaluate the performance of the CRM2S-MS, Figure 2 displays the dis-
tribution of the toxicity probability for the selected dose combinations across 1,000
simulated trials. We can see that under scenarios 1 to 7, the toxicity probabilities of
the selected MTD combinations are all centered around the target toxicity probabil-
ity of 0.3. In scenario 8, for which all the doses were overly toxic, most of the trials
were terminated early. Without loss of generality, we show the contour of the toxicity
probabilities of the dose combinations under scenario 4 in Figure 3, so that we can visu-
alize the toxicity surface under the fitted model. In other scenarios, we observe similar
patterns in which toxicity increases with respect to both discrete and continuous doses.
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Figure 2: Distributions of the true toxicity probabilities of the selected dose combination
over 1,000 simulated trials.
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Figure 3: Toxicity probability contours of the fitted model under scenario 4.
4.2 Sensitivity Analysis
We conducted a sensitivity analysis to investigate the robustness of our two-stage CRM
design when the dose-toxicity model is misspecified. Specifically, we simulated data
from the model with a quadratic term,
pid(z) = p
exp(α−β(z−z0)−γ(z−z0)2)
d , (6)
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while we still used model (3) for dose finding. For ease of comparison, we controlled the
toxicity probabilities of the discrete doses to be the same as those in Table 1, and varied
the target continuous doses for different values of γ under each scenario. Table 2 shows
that under all the scenarios the selection probabilities of the discrete doses were very
similar to those in Table 1, and the estimated continuous doses were generally close to
the target values, suggesting that the proposed two-stage CRM design is quite robust
to model misspecifications.
Table 2: Sensitivity analysis of the two-stage CRM with a toxicity target of φ = 30%.
We present the selection percentage for each discrete dose (the target dose in boldface),
the average number of patients treated at each dose, and the median of the estimated
continuous dose along with the 25th and 75th percentiles.
Two-stage Agent A (Discrete) Agent B (Continuous) Ave. Ave.
None
Design 1 2 3 4 5 True Estimated # tox # pts
Scenario 1 0.22 0.35 0.45 0.60 0.70
γ = 0.5 62.0 25.2 1.5 0.1 0 1.34 1.26(1.13,1.41) 14.1 32.6 11.2
# patients 18.5 10.1 3.2 0.7 0
γ = 1 62.8 24.3 1.7 0.2 0 1.29 1.21(1.12,1.35) 14.3 32.6 11.0
# patients 18.7 10.0 3.1 0.7 0.1
γ = 2 63.7 22.8 1.8 0.2 0 1.24 1.20(1.11,1.31) 14.3 32.5 11.5
# patients 19.0 9.6 3.1 0.7 0.2
Scenario 2 0.10 0.25 0.45 0.55 0.65
γ = 0.5 30.8 62.1 5.6 0.6 0 1.23 1.23(1.11,1.40) 11.8 35.7 0.9
# patients 9.8 18.0 6.1 1.5 0.3
γ = 1 31.8 61.2 5.3 0.2 0 1.20 1.20(1.11,1.35) 11.8 35.5 1.5
# patients 9.9 17.9 5.9 1.5 0.3
γ = 2 32.4 61.9 4.4 0.3 0.1 1.17 1.16(1.09,1.26) 12.0 35.7 0.9
# patients 10.1 17.9 6.0 1.4 0.3
Scenario 3 0.14 0.21 0.35 0.49 0.63
γ = 0.5 18.5 62.1 14.3 2.4 0.1 1.38 1.31(1.18,1.49) 11.5 35.2 2.6
# patients 7.8 16.2 7.7 2.8 0.7
γ = 1 19.5 62.7 13.3 2.1 0 1.32 1.26(1.15,1.39) 11.6 35.2 2.4
# patients 8.0 16.3 7.5 2.8 0.7
γ = 2 20.1 61.6 13.7 2.2 0 1.26 1.22(1.12,1.32) 11.8 35.2 2.4
# patients 8.2 16.1 7.5 2.8 0.7
Scenario 4 0.08 0.15 0.22 0.35 0.50
γ = 0.5 4.3 32.1 38.9 21.4 2.7 1.34 1.20(1.09,1.40) 10.4 35.8 0.6
# patients 4.1 9.7 11.3 7.7 3.1
γ = 1 4.0 31.8 39.1 21.8 2.8 1.29 1.16(1.08,1.31) 10.5 35.8 0.5
# patients 4.1 9.6 11.3 7.7 3.1
γ = 2 4.4 35.1 36.9 20.3 2.7 1.24 1.14(1.07,1.26) 10.7 35.8 0.6
# patients 4.1 10.1 11.1 7.5 3.0
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Table 2, continued.
Two-stage Agent A (Discrete) Agent B (Continuous) Ave. Ave.
None
Design 1 2 3 4 5 True Estimated # tox # pts
Scenario 5 0.05 0.10 0.20 0.40 0.54
γ = 0.5 1.1 28.2 48.0 20.9 1.6 1.41 1.23(1.11,1.42) 10.4 35.9 0.2
# patients 2.9 8.5 14.1 8.0 2.5
γ = 1 0.7 31.5 49.0 17.7 1.0 1.34 1.20(1.10,1.36) 10.5 35.9 0.1
# patients 2.7 8.9 14.1 7.9 2.4
γ = 2 1.0 32.5 49.7 15.7 0.9 1.28 1.16(1.09,1.28) 10.6 35.9 0.2
# patients 2.7 9.1 14.3 7.5 2.3
Scenario 6 0.02 0.08 0.12 0.20 0.40
γ = 0.5 0.1 4.2 15.2 56.3 24.2 1.41 1.22(1.10,1.40) 9.5 36 0
# patients 2.3 3.5 6.8 12.9 10.4
γ = 1 0.1 4.7 17.3 54.3 23.6 1.34 1.19(1.09,1.34) 9.6 36 0
# patients 2.3 3.7 7.0 12.8 10.2
γ = 2 0.1 5.2 16.5 56.9 21.3 1.28 1.14(1.07,1.26) 9.8 36 0
# patients 2.4 3.7 6.9 13.1 10.0
Scenario 7 0.02 0.05 0.08 0.12 0.25
γ = 0.5 0 0.9 2.4 23.7 73.0 1.23 1.24(1.12,1.38) 8.7 36 0
# patients 2.2 2.5 3.6 7.3 20.5
γ = 1 0 1.2 2.5 23.3 73.0 1.20 1.21(1.10,1.35) 8.7 36 0
# patients 2.2 2.6 3.5 7.3 20.4
γ = 2 0 0.7 3.1 23.3 72.9 1.17 1.17(1.08,1.27) 8.9 36 0
# patients 2.2 2.5 3.6 7.5 20.2
Scenario 8 0.50 0.60 0.65 0.70 0.80
γ = 0.5 24.3 0.2 0 0 0 9.1 13.5 75.5
# patients 11.9 1.3 0.3 0 0
γ = 1 24.3 0.2 0 0 0 9.1 13.5 75.5
# patients 11.9 1.3 0.3 0 0
γ = 2 24.3 0.2 0 0 0 9.1 13.5 75.5
# patients 11.9 1.3 0.3 0 0
5 Conclusion
We have proposed a Bayesian adaptive two-stage dose-finding design for drug-combination
trials with a continuous-dose agent and a discrete-dose agent. This two-stage procedure
locates the appropriate dose for the discrete-dose agent in the first stage, then estimates
the best dose for the continuous-dose agent through a two-parameter CRM model in
the second stage. We have also incorporated model selection throughout the two-stage
procedure to reduce the chance of a poor trial performance due to misspecification of
the toxicity probabilities in the CRM. Our simulation studies have indicated that the
two-parameter CRM model has desirable properties and yields good design operating
characteristics.
For drug-combination trials, multiple MTDs may exist due to the toxicity equivalence
contour. The two-stage CRM provides a natural and intuitive way to find one of the
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MTDs, by first coarsely searching over the discrete doses and then fine searching through
the continuous dose. In fact, given a known target toxicity probability, the continuous
dose can be predicted at each step of dose finding. As more data are collected in the
course of the trial, such prediction would become more precise. In addition, the discrete
dose is not completely fixed in stage II when we search for the continuous dose. There
is still some room to adjust the discrete dose in case it was over- or under-estimated in
stage I. This feature inherits the spirit of jointly modeling the doses of both agents in a
drug-combination trial.
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